Placeholder Banner

Influential investor, Wende Hutton, to Speak at #BIF19

Theresa Brady
Theresa Brady
July 17, 2019

In a few short months BIO will be hosting the BIO Investor Forum (#BIF19) for the 17th time. The event’s long history is testament to the continued appetite for partnerships, collaborations and investment in the exciting world of early stage biotech companies on the cusp of medical breakthroughs that can change and save lives.

One of the first announced fireside chat speakers for the October (22-23) event is a seasoned investor who has spent much of her career championing innovation in medicine, supporting both devices and therapeutics companies. Wende Hutton, General Partner at Canaan—an early-stage venture capital firm, will share her expertise on what it takes to bring innovations to the marketplace and to patients.

Hutton has 24 years of biotech, medical device, and healthcare IT investment experience. Armed with a Harvard MBA, she has helped companies build strong teams, overseeing seven IPOs and six acquisitions while bringing over a dozen medical devices and treatments to the market.

With 2019 on pace to be the second-highest year on record for venture investments in biotech startups (2018 was the record), #BIF19 is a perfect place for Hutton to lead a discussion about what it takes to go from a start-up to a full-scale commercial biotech company.

BIO’s Investor Forum, held yearly in San Francisco, is designed to accelerate growth within the biopharma industry, catering to entities early in their lifecycle and stakeholders looking to support them and get more innovative treatments to helping patients sooner.

During the upcoming months, more conference details will become available and shared in this space. Topics being explored are:

  • What characterizes a successful biopharma-digital therapeutic alliance?

  • How are new CFIUS rules affecting your China investor fundraising options?

  • What types of diagnostics can build reimbursement strategies most easily?

  • What oncology targets seen most promising but not overstocked with programs?

  • Which new CNS treatment approaches are making the most clinical progress?

  • How can tax-advantaged “Opportunity Zones” accelerate fundraising?

  • What licensing ripples are formed by large biopharma’s M&A deal fever?

  • What new models are investors creating to accelerate translational research from universities into corporate drug development?

  • How should you adapt your board recruitment to ensure compliance with board diversity regulations?

  • What bottlenecks can be overcome to cut clinical trial costs in half?

  • What new alternative funding models are emerging to supplement venture capital?

  • How should you react if biotech investors are suffering IPO and M&A fatigue?

  • Which AI-based approaches are reliably accelerating drug development?

  • What evidence should gene therapy developers be gathering now to demonstrate value compellingly to payers later?


More information can be found at